A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer’s disease model
© Wang et al.; licensee BioMed Central Ltd. 2014
Received: 20 August 2013
Accepted: 7 April 2014
Published: 12 May 2014
Vaccination against amyloid-β protein (Aβ42) induces high levels of antibody, making it a promising strategy for treating Alzheimer’s disease (AD). One drawback in the past was that clinical trial approval was withheld because of speculation that the Aβ42 vaccine induces CD4+ T cell infiltrations into the central nervous system. To reduce T-cell activation while concomitantly maintaining high anti-Aβ42 titers is a great challenge in immunology.
We aimed to demonstrate that coimmunization with Aβ42 protein and expression plasmid can be beneficial in a mouse AD model and can prevent inflammation. We immunized the AD mice with the coimmunization vaccine and assessed behavior change and Aβ42 deposition. Furthermore, to determine the safety of the coimmunization vaccine, we used an induced Aβ42-EAE model to mimic the meningoencephalitis that happened in the AN-1792 vaccine clinical phase II trial and tested whether the coimmunization vaccine could ameliorate T-cell-mediated brain inflammation.
The coimmunization vaccination reduced Aβ plaques and significantly ameliorated cognitive deficit while inhibiting T-cell-mediated brain inflammation and infiltration. These studies demonstrate that the coimmunization strategy that we describe in this article can ameliorate AD pathology without notable adverse effects in mice.
A coimmunization strategy leading to the development of a safe immunotherapeutic/preventive protocol against AD in humans is warranted.
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive cognitive dysfunction, massive loss of neurons and deposition of amyloid plaques and neurofibrillary tangles . The pathological accumulation of amyloid is possibly due to site-specific abnormal processing of amyloid precursor protein (APP). Investigators in previous studies have shown that deposition of amyloid-β protein (Aβ), particularly the Aβ40 and Aβ42 forms, in amyloid plaques is one of the hallmarks of the disease [2–4] and could trigger a T-cell-mediated (auto)immune reactions . A large body of evidence supports the amyloid cascade hypothesis, which states that accumulation of Aβ is the initiating step for the onset of AD. Therefore, most research has centered on Aβ, and many Aβ-related therapeutic strategies have been proposed and/or developed, including immunotherapy [6–9].
After successful experiments in AD model mice , researchers in a phase IIa immunotherapy trial in patients with mild to moderate AD showed that about 20% of vaccinees had immunoglobulin G (IgG) responses. However, the trial had to be stopped because 6% of the vaccinated patients developed meningoencephalitis . Pathology reports indicated that the cases of meningoencephalitis were severe, which suggested that vaccine-induced T-cell infiltration might be the cause . This raised a critical question about how to develop a vaccine that can elicit a high level of antibody against Aβ42 antigen while preventing T-cell responses [12–16]. Several approaches to answering this question have been employed, including the use of truncated versions of Aβ42 that exclude T-cell epitopes (for example, Aβ1–28, Aβ1–16, Aβ1–14 and Aβ1–9). In many of the previously reported Aβ immunization studies, researchers have found reduced cerebral Aβ levels and/or improved cognition in mice, nonhuman primates and humans [15, 17–21]. Monoclonal antibodies against Aβ42 have been used in passive vaccination [22–25], including bapineuzumab, solanezumab and ponezumab [26–28]. Although selecting the B-cell epitopes for vaccines could avoid the T-cell response, short peptides do not have the same strong ability to stimulate a high titer of IgG and would therefore need to be modified, adding to the production cost and complexity of vaccine studies in AD . Passive immunization with an antibody may not stimulate the unwanted T-cell response, but antibodies are more expensive than protein or DNA vaccines and do not last very long in vivo. The various strategies being used for vaccine development are at different stages, and some have a bearing on the use of DNA and protein coimmunization or the induction of anti-inflammatory, regulatory T cells (Tregs). Lambracht-Washington et al. demonstrated a novel strategy of using peptide prime plus DNA boost immunization regimens . These regimens induced higher levels of anti-Aβ42 antibody responses, mainly of T helper type 2 (Th2) cells rather than Th1 cells, in contrast to traditional Aβ42 peptide immunizations. Furthermore, T-cell responses were lower before than after peptide immunization. Although the protocol demonstrated a potential alternative way to generate high levels of antibody against Aβ plaques, T-cell responses potentially could be autoreactivated if multiple immunizations were required. Liu et al. used a diphtheria toxoid (DT)-conjugated Aβ1–15 vaccine that deleted the T-cell epitope and found that it upregulated CD25+ Tregs. Whether these regulatory T cells were specific for the Aβ peptide and had a major anti-inflammatory impact needs to be further investigated. The results obtained with other vaccines have indicated a capacity to induce T cells with the CD4+CD25+Foxp3+ regulatory phenotype that is responsive to Aβ15-DT, but not to the Aβ1–15 epitope or to intact Aβ1–40/Aβ1–42 . This finding indicates that induction of antigen-specific regulatory T cells (iTregs), even when not directly against an Aβ antigen, may improve the safety of Aβ-based vaccines against inflammation.
Tregs have been shown to be important regulators of tolerance, which suggests the possibility of developing direct strategies to use these cells to prevent or even to treat autoimmune inflammation . Various approaches to inducing Treg cells to constrain autoreactive T cells have been explored. Notably, the induction of antigen-specific iTreg cells targeted to allergy, asthma and autoimmune disease antigens is considered a promising immunomodulatory strategy [32–34]. Therefore, it may be possible to develop a strategy to induce antigen-specific iTreg cells targeted against Aβ42 antigen without affecting the antibody response.
We have previously reported that coimmunization with a DNA vaccine and its encoded protein antigen induced iTreg to inhibit antigen-specific T-cell function in vivo. Importantly, this suppression had no effect on antibody production . In this article, we demonstrate that coimmunization with Aβ42 protein and a DNA vaccine encoding Aβ42 in an AD mouse model induced high titers of anti-Aβ42 antibodies, which resulted in clearance of amyloid plaques and improvement in cognitive behavior. Strikingly, the coimmunization also induced antigen-specific iTreg cells that ameliorated T-cell-mediated brain inflammation. We show that the prevention of inflammation is due, at least in part, to the suppressive effects of iTregs on CD4+ effector T-cell (Teff) function.
Adult female C57BL/6 mice (6 to 8 weeks of age) were purchased from the Animal Institute of the Chinese Medical Academy (Beijing, China). APP695 mice (10-month-old, C57BL/6 background) [35–37] were obtained from the Chinese Academy of Medical Sciences & Comparative Medical Center. Mice that coexpress Foxp3 and enhanced green eGFP (Foxp3-eGFP, C57BL/6 background) were kindly provided by Dr Minghui Zhang (Tsinghua University, Beijing, China). APP/PS1 mice (C57BL/6 background)  were kindly provided by Mathias Jucker, Hertie Institute, Tübingen, Germany. All mouse protocols were approved by the animal welfare committees of China Agricultural University, Fudan University and the Institute for Age Research. All animals were maintained under specific pathogen-free conditions and a 12-hour light–dark cycle.
Recombinant eukaryotic and prokaryotic plasmids were identified by restriction enzyme digestion and verified by sequencing analysis. The inserts were subcloned into either a pVAX1 or pET28a vector (Invitrogen, Carlsbad, CA, USA). Expression levels were examined by Western blot analysis 48 hours after transfection of BHK cells (American Type Culture Collection, Manassas, VA, USA) for inserts in the pVAX backbone or 8 hours after induction of transfected Escherichia coli with 0.1 mM isopropyl-β-D-thiogalactopyranoside for inserts in pET28 vectors.
Female C57BL/6 mice (6 to 8 weeks old) and APP695 mice (both male and female, 10 months old) were immunized with various regimens via the tibialis anterior muscle on days 0, 14, 28 and 70. These regimens were as follows: Aβ42 protein, 200 μg/mouse; pVAX1-Aβ42, 100 μg/mouse; coimmunization, a mixture of 200 μg of Aβ42 protein and 100 μg of pVAX1-Aβ42; a positive control in which mice were first immunized with 200 μg of Aβ42 protein emulsified with complete Freund’s adjuvant (CFA; Sigma-Aldrich, St Louis, MO, USA), and then second, third, fourth and fifth immunizations were delivered with 200 μg of Aβ42 protein in incomplete Freund’s adjuvant (IFA; Sigma-Aldrich).
T cells were isolated from the spleens of immunized C57BL/6 mice or APP695 transgenic mice on day 7 after the fourth immunization. For intracellular staining, T cells were stimulated with Aβ42 protein at 10 μg/ml for 8 hours and subsequently treated with brefeldin A (BFA; BD Biosciences, San Diego, CA, USA) for 2 hours in vitro. The cells were blocked with BD Fc Block antibody (BD Biosciences) in phosphate-buffered saline (PBS) for 30 minutes at 4°C before being fixed with 4% paraformaldehyde and permeabilized with saponin (Sigma-Aldrich). The splenocytes were intracellularly stained with the appropriate concentrations of phycoerythrin (PE)-labeled antibodies, including anti-Foxp3, interleukin 10 (anti-IL-10), transforming growth factor β (anti-TGF-β), interferon γ (anti-IFN-γ), anti-IL-4 and PE-cyanine 5.5 (PE-Cy5.5)-labeled anti-CD25 antibodies (eBioscience, San Diego, CA, USA) and fluorescein isothiocyanate (FITC)-labeled anti-CD4 antibody (eBioscience) for 30 minutes at 4°C. The cells were washed and analyzed with a FACSCalibur flow cytometer equipped with CellQuest Pro software (BD Biosciences).
For Aβ plaque immunohistochemistry, frozen brain sections taken from 9-month-old APP/PS1-transgenic mice were warmed to room temperature for 30 minutes and fixed in ice-cold acetone for 5 minutes before being air-dried for 30 minutes. The sections were incubated with normal serum for 30 minutes to block nonspecific binding of immunoglobulin. The tissue sections were reacted first for 1 hour at room temperature or overnight at 4°C with (1) antisera induced by coimmunization or by protein vaccination, or (2) with sera from untreated mice (all sera were at 1:200 dilution) or (3) with monoclonal antibody 3552 (1:2,000 dilution) as a positive control. All serum dilutions were made in primary antibody dilution buffer. After incubation, the sections were washed three times with PBS, then incubated with Alexa Fluor 555–labeled secondary antibody (1:1,000 dilution; Invitrogen) for 30 minutes at room temperature and washed three times with PBS. After brush transfer of sections onto glass slides, plaques were detected by fluorescence microscopy (Carl Zeiss, Jena, Germany) at 546-nm emission. The nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI), and the sections were incubated with 1 μg/ml DAPI for 5 minutes in the dark at room temperature, washed twice with PBS and detected at 405-nm emission.
T-cell proliferative response
Single-lymphocyte suspensions were obtained from the spleens of immunized C57BL/6 mice or APP695 mice on day 7 after the fourth immunization. Cells in RPMI 1640/Ham’s F-10 Nutrient Mix medium (GIBCO, Eggenstein, Germany) containing 10% fetal bovine serum were used to determine the T-cell proliferative response by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) staining after Aβ42 stimulation in vitro for 72 hours. MTT-stained cells were analyzed using an enzyme-linked immunosorbent assay (ELISA) plate reader (Magellan; Tecan Austria, Grodig, Austria) at 450-nm absorbance. The data are expressed in SI units, and the means are the product of (stimulated cells – medium) ÷ (unstimulated cells –medium) detected at 450-nm absorbance.
Measurement of Aβ42 protein-specific antibodies
The level of anti-Aβ42 serum IgG antibodies was determined by ELISA in 96-well plates coated with Aβ42 protein at 10 μg/ml and detected with a secondary goat anti-mouse IgG antibody conjugated with horseradish peroxidase (HRP; Bio-Rad Laboratories, Hercules, CA, USA). Absorbance at 450 nm was measured with a Magellan ELISA plate reader.
Fibrillar Aβ deposition and histological analysis
Thioflavin S staining was used, which is common for fluorescent staining of fibrillar amyloid deposition . Brain tissue was fixed in 4% neutral buffered formalin and mounted in paraffin blocks. After deparaffinization and hydration, the sections were washed in PBS and incubated in a solution containing 0.25% potassium permanganate and 1% oxalic acid until they appeared white. The sections were then washed in water and stained for 3 minutes with a solution of 0.015% thioflavin S in 50% ethanol. Finally, the sections were washed in 50% ethanol and in water, then dried and dipped in Histo-Clear (National Diagnostics, Atlanta, GA, USA) histological clearing agent before being coverslipped with Permount (Sinopharm Chemical Reagent Co., Ltd, Shanghai, China) mounting medium . The sections were examined using three equidistant sections per animal at 488-nm emission. Quantification and statistical analysis of staining were carried out using Image-Pro Plus version 6.0 software (Media Cybernetics, Rockville, MD, USA).
For Aβ plaque immunohistochemistry, brain tissue was fixed in 4% neutral buffered formalin and mounted in paraffin blocks. After deparaffinization and hydration, tissue sections in citric acid buffer solution (pH 6.0, antigen repair) were placed in the microwave for antigen retrieval. Next, sections were put into 3% hydrogen peroxide solution, incubated at room temperature for 25 minutes and placed in the PBS solution (pH 7.4) and then shaken and washed for 5 minutes each time to block endogenous peroxidase. The tissue sections were reacted first for 1 hour at room temperature or overnight at 4°C with monoclonal antibody anti-Aβ (1:200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-CD4 (1:100 dilution; ABclonal, Wuhan, China). All primary antibodies were diluted in 5% bovine serum albumin (BSA)/PBS buffer and incubated with the sections before they were washed three times with PBS and then incubated with HRP-labeled secondary antibody (1:200 dilution; KPL, Gaithersburg, MD, USA) for 50 minutes at room temperature. 3,3′-Diaminobenzidine coloration (Invitrogen) was carried out, and the reaction product was kept at room temperature without light for 10 minutes and stained with hematoxylin and eosin (H&E). All of the sections were detected with an EVOS FL cell imaging system (Life Technologies, Carlsbad, CA, USA) in visible light. Quantification and statistical analysis of staining were carried out using Image-Pro Plus version 6.0 software (Media Cybernetics).
Microhemorrhage staining and hematoxylin and eosin staining
For microhemorrhage staining, brain tissue taken from 14-month-old AD mice after the fifth immunization was mounted and stained for hemosiderin using 2% potassium ferrocyanide in 2% hydrochloric acid for 15 minutes, followed by counterstaining in a 1% neutral red solution for 10 minutes at room temperature. Microhemorrhage events in the form of Prussian blue-positive profiles were observed on all brain tissue sections from each mouse by microscopy (Life Technologies) in visible light. For H&E staining, the brains taken from the Aβ42 autoimmune encephalomyelitis (Aβ42-EAE) mice on day 21 after induction were fixed in 4% paraformaldehyde. Paraffin sections were stained with H&E and observed by microscopy (Life Technologies) in visible light.
Plasmid expression tests
The BHK-21 cell line was used for detecting pVAX1-Aβ42 transfection and expression with Lipofectamine 2000 reagent (Invitrogen). The BHK-21 cells were put into 24-well plates at 105 per well. The plasmid was transfected using 1 μg of plasmid and 2 μl of Lipofectamine 2000 in 500 μl of serum-free medium. Serum-free medium was replaced after 3 hours with serum-containing medium. The whole operation was carried out according to the Lipofectamine 2000 kit instructions. The cells were collected in radioimmunoprecipitation assay lysis buffer (Beyotime, Shanghai, China) at 48 hours after transfection, and the plasmid expression was tested by Western blot analysis. The primary anti-Aβ42 antibody (1:1,000 dilution; Santa Cruz Biotechnology) or glyceraldehyde 3-phosphate dehydrogenase antibody (anti-GAPDH; Abcam, Cambridge, MA, USA) was incubated overnight at 4°C and washed. The HRP-labeled anti-mouse IgG secondary antibodies (1:3,000 dilution; Santa Cruz Biotechnology) were incubated for 1 hour at room temperature and washed. The blots were analyzed by chemiluminescence detection.
Behaviors of APP695 mice were measured using the open-field test. We used EthoVision XT monitoring and analysis software (EthoVision XT; Noldus Ltd, Wageningen, the Netherlands) and a 50 × 50–cm open field. The open field was divided into three areas, which included the peripheral zone (zone 1) and the central zone (zones 2 and 3). Zone 1 was 8 cm away from the edge of the open field. Zone 3 occupied the central area, which was 16% of the total. The remaining area was designated zone 2. Each mouse had 5 minutes of free movement in the open field. We recorded the length of time that each mouse stayed in each zone and the frequency that the mouse was in the mobile state. Mobility was the state variable and included three different variables: immobile, mobile and highly mobile. The mouse was considered to be immobile when the change in area of the mouse between current sample and the previous sample (referred to as the changed area) was <20%, highly mobile when the changed area was >60% and mobile when the changed area was between 20% and 60%. The amount of time spent in the peripheral zone is a manifestation of thigmotaxis . Room temperature was kept constant, and the light level was even across the open field. The open field was wiped clean with 75% alcohol and dried before each experiment to remove residual odors.
Morris water maze
Learning and memory were tested using the Morris water maze (MWM) 1 day after the end of the open-field test. The protocol for the MWM test was modified from previously reported methods [42, 43]. Briefly, the apparatus included a pool with a diameter of 100 cm that was filled with opaque water at 20°C ± 1. An escape platform 15 cm in diameter was placed 0.5 cm below the water surface. Geometric objects with contrasting colors were set at the remote ends of the water tank as reference points. Room temperature was kept constant at 20°C ± 1, and the light level was even throughout the room. Spatial memory was assessed by recording the latency time for the animal to escape from the water onto a submerged escape platform during the learning phase. The platform was in zone 4 and defined as zone 5. The mice were studied in four trials per day for 3 consecutive days. The mice were allowed to stay on the platform for 15 seconds before and after each trial. The time that it took for an animal to reach the platform (the latency period) was recorded. Twenty-four hours after the learning phase, the mice swam freely in the water tank without the platform for sixty seconds, and the time spent in the region was recorded. Monitoring was performed with a video tracking system (EthoVision XT).
Detection of insoluble Aβ42 by enzyme-linked immunosorbent assay
The brains of APP695 mice were extracted in Tris-HCl buffer at pH 8.0 and centrifuged at 4°C and 20,000 × g for 20 minutes. After we discarded the supernatant, we washed the pellet in Tris-HCl pH 8.0 buffer three times and homogenized it in buffer composed of 6 M guanidine hydrochloride with -Tris-HCl pH 8.0. After it was sonicated at room temperature for 30 seconds, the sample was incubated for 1 hour at room temperature and then centrifuged at 4°C and 20,000 × g for 20 minutes. Samples were diluted 1:12 in ELISA bicarbonate buffer pH 9.6, incubated in 96-well plates at 4°C overnight and assayed with a primary anti-Aβ antibody (2B9, diluted 1:500; Santa Cruz Biotechnology) and secondary goat anti-mouse IgG antibody conjugated with HRP (diluted 1:1,000; Bio-Rad Laboratories). Absorbance at 450 nm was measured with an ELISA plate reader (Magellan).
Analysis of inflammatory cytokines
Brain tissue was homogenized by ultrasonication in cold PBS after perfusion. After supernatants were centrifuged at 8,000 rpm/min at 4°C for 30 minutes, they were diluted 1:10 with cold PBS and assayed by cytometric beads array (CBA; BD Biosciences) so that we could detect expression levels of IL-6, IL-1β, tumor necrosis factor α (TNF-α) and IFN-γ.
Induction of experimental autoimmune encephalomyelitis
We used a myelin oligodendrocyte glycoprotein–induced EAE (MOG-EAE) model. Female 8-week-old C57BL/6 mice were immunized with 200 μg/100 μl MOG 35–55 peptide fragment emulsified in 100 μl of 5× CFA (500 μg/100 μl killed H37Ra/CFA; Sigma-Aldrich). We injected a total of 200 μl of CFA into the animals, which was divided between two subcutaneous posterior auricular sites. Pertussis toxin (PT) (200 ng/mouse; Sigma-Aldrich) was injected intraperitoneally on days 0 and 1 .
Aβ42-EAE-induced brain inflammation
To mimic the results obtained from AN-1792 vaccine-induced brain inflammation and encephalitis , we used Aβ42 protein (200 μg/100 μl) to replace MOG in the MOG-EAE model described in the preceding subsection and used this Aβ42-EAE model as the positive experimental control. After EAE induction, the mice were immunized using various regimens via the tibialis anterior muscle on days 0 and 14. The regimens used were as follows: the protein group was immunized with Aβ42 protein at 200 μg/mouse, the plasmid group was immunized with pVAX1-Aβ42 at 100 μg/mouse and the coimmunization group was immunized with a mixture of 200 μg of Aβ42 protein and 100 μg of pVAX1-Aβ42. We used the untreated MOG-EAE or Aβ42-EAE model mice as positive controls. On day 21, the mice were anesthetized before heart perfusion with cold PBS. The brain tissues were isolated and digested with trypsin (MACGENE, Beijing, China) at 37°C for 0.5 hour to obtain single-cell suspensions. The brain cells were stained with FITC/anti-CD3 and allophycocyanin (APC)/anti-CD4 antibodies (eBioscience).
CD25− induced antigen-specific regulatory T-cell transfer assay
Foxp3-eGFP mice were used as donor mice and were coimmunized intramuscularly twice (with a 14-day interval) with a mixture of 200 μg of Aβ42 protein and 100 μg of pVAX1-Aβ42. Splenocytes were isolated from the coimmunized donor mice 7 days after the second immunization, stained with APC anti-mouse CD4+ and Foxp3+ and PE-Cy5-labeled anti-mouse CD25+ antibodies, and sorted using a BD FACSAria II flow cytometer. Any cells stained for CD25+ were excluded. The sorted CD25− iTreg cells were adoptively transferred intravenously at 106 per animal into C57BL/6 mouse recipients that had been immunized twice with CFA-emulsified Aβ42 protein to induce Aβ42-EAE-induced inflammation.
On day 21, all recipients were anesthetized, and heart perfusion was performed with cold PBS. The brains were separated and digested with trypsin at 37°C for 0.5 hour to obtain single-cell suspensions as described in the preceding subsection. All cells were stained with FITC/anti-CD3 and APC/anti-CD4 antibodies.
The results are presented as means ± SD. Except for data derived from the MWM experiments, statistical analysis was carried out by parametric one-way analysis of variance (ANOVA) and t-tests were used for comparisons between two groups. In the MWM tests, escape latency in the hidden platform trial was analyzed using two-way ANOVA of repeated measures, and one-way ANOVA was conducted to assess the data obtained from the probe trial. Differences were considered to be statistically significant at P < 0.05.
Aβ42 coimmunization induces high immunoglobulin G titer anti-Aβ42 antibodies capable of binding to amyloid plaques
Coimmunization of Aβ42 reduces plaque formation in APP695 mice
The brain cortex sections were stained with thioflavin S, and the number of plaques as well as the total plaque area were calculated (Figures 2C and 2D). As expected, the APP695 model group had the highest plaque counts, and the immunized groups had lower plaque counts, albeit not significantly. However, the plaque areas were significantly smaller in both the coimmunization and protein-immunized groups than in the APP695 model group (Figure 2B). This finding is in good agreement with the results obtained with immunohistochemical staining (Figures 2A and 2B). The results show that the APP695 mice also had developed both diffused and some focused Aβ deposits and that the immunizations with vaccines could facilitate clearing of the plaques. In summary, these results indicate that both the coimmunization and protein immunization regimens effectively reduced plaque loads in APP695 mice.
Coimmunization of Aβ42 attenuates abnormal exploratory activity of APP695 mice in open-field test
Coimmunization of Aβ42 improves the learning and memory of APP695 mice in Morris water maze tests
To assess spatial learning and memory function, all animals underwent MWM tests 14 days after their last immunization. As shown in Figure 3C, there was a significant difference overall in escape latency between the four groups (group effect: F(4,36) = 11.13, P < 0.01; training day effect: F(4,144) = 12.45, P < 0.01; and group × training day interaction: F(12,144) = 1.087, P > 0.05). The latency to find the submerged platform decreased every day in each group, but the escape latency in the untreated APP695 mice was significantly longer than that of the WT group (P < 0.01). The coimmunized and protein-immunized AD mice showed significantly decreased escape latencies compared with those of the untreated APP695 controls (P < 0.05), almost down to WT levels. The DNA-immunized mice also improved their learning behavior, but not significantly compared to the coimmunization and Aβ42 protein-immunized groups (data not shown).
In a probe test, the frequency of crossing the platform was measured for 60 seconds on the fourth day after the last acquisition test. As shown in Figure 3D, there was an overall significant difference in the frequency of crossing the platform between the five groups (F(4,36) = 10.45, P < 0.01). The latency was decreased in the untreated APP695 mice compared with the WT mice (P < 0.01). Duration times in the platform zone were significantly increased (P < 0.01) among both the coimmunized and protein-immunized groups compared with the untreated APP695 mice, whereas the DNA-immunized group showed no improvements compared with the AD mice (P > 0.05) (data not shown). Taken together, these results show that that Aβ42 protein immunization as well as coimmunization efficiently ameliorated cognitive deficits in AD mice.
Coimmunization affects inflammatory cytokines in brain tissue
Coimmunization suppresses T-cell proliferation by inducing CD25− iTreg cells
We next tested whether the iTreg cells affected T-cell production of inflammatory cytokines. After immunization, CD4+ T cells were isolated, and intracellular staining was performed. As shown in Figure 5C, the level of IFN-γ was downregulated, but levels of Foxp3, IL-10 and TGF-β were upregulated, by the coimmunization regimen compared to the Aβ42 protein–immunized group. In contrast, no effect on the level of IL-4 was observed (Figure 5C). These results suggest that the coimmunization protocol induced a Th1-suppressive response, but did not affect the humoral response.
Coimmunization prevents induced experimental autoimmune encephalomyelitis
Coimmunization-induced regulatory T cells suppressed brain inflammation
These data demonstrate that the coimmunization regimens with Aβ42 protein and Aβ42 coding DNA-induced iTregs strongly reduced brain inflammation and infiltration of T cells into the brain. At the same time, a robust anti-Aβ42 antibody response was elicited that effectively reduced plaque formation. Therefore, coimmunization is an attractive and novel strategy for use in AD vaccine development.
In this study, the co-immunization strategy that we developed was applied for the first time in an AD mouse model. Our goal in mixing the Aβ42 protein and Aβ42 DNA vaccine was to achieve high levels of anti-Aβ42 antibodies with concurrent inhibition of T-cell-mediated inflammation. This should ameliorate cognitive deficits while lowering the adverse effects of neuroinflammation in conventionally vaccinated mice and humans. We demonstrate that the coimmunization of DNA encoding Aβ42 plus Aβ42 protein in APP695 mice indeed induced higher levels of IgG against Aβ, resulting in reduction of Aβ load and dramatically improved behavior in Morris water maze and open-field tests. The coimmunization induced high levels of iTreg with a strong ability to suppress CD4+ T-mediated inflammation. This resulted not only in suppression of T-cell proliferation but also, importantly, in reduced expression of inflammatory cytokines, including IFN-γ, IL-1β, IL-6 and TNF-α in brain tissue samples. We found small numbers of CD4+ T cells in the brains taken from the protein vaccine group (Additional file 2: Figure S3). So we speculated that the source of increased inflammatory stimuli, such as IFN-γ and TNF-α, was the infiltrated T cells. Expression of these cytokines is thought to lead to T cell infiltration and is associated with in situ lesions [5, 51, 52]. We also looked for microhemorrhaging in the brain tissue by applying Prussian blue staining and found that this coimmunization vaccine did not induce microhemorrhaging (Additional file 4: Figure S2). We did find one mouse in the protein-immunized group that had a Prussian blue–positive spot, but we could not find cerebral amyloid angiopathy (CAA) when we applied Congo red staining in both immunized groups up to 10 months after their initial immunization, suggesting that these animals may not yet have reached the age of intense CAA. Therefore, future studies in older mice are warranted to investigate this problem.
The protein Aβ42 that we have used in this study has one main difference from AN-1792, the vaccine used in a phase II trial conducted with human patients . We used CFA and IFA as adjuvants in our protein vaccine, whereas QS-21 was the adjuvant used in AN-1792 . Both adjuvants not only augment antibody responses but also elicit strong helper T-cell responses, producing cytokines such as IFN-γ [53–58], which can cause perivenular inflammatory encephalomyelitis during vaccination . In earlier animal experiments, however, CFA and IFA were demonstrated to improve the efficiency of Aβ42 antibody production to attenuate AD-like pathology in the PDAPP mouse .
Our data show that the efficacy of the coimmunization vaccine to reduce plaque load is comparable to a “conventional”, well-established protein vaccine, but at the same time is superior because it causes less side effects.
The main concern with regard to current protein-based Aβ42 AD vaccines is that they can cause meningoencephalitis in AD patients, because vaccination with Aβ42-based vaccines might induce T-cell activation and infiltration into the central nervous system . To avoid this problem, several alternative approaches are currently being developed, including the use of monoclonal antibody against Aβ42 for passive immunization or a truncated form of Aβ42 as a vaccine, such as Aβ1−15-DT conjugate, which could increase antibody titers by adding nonrelevant epitopes of a DT carrier for T helper cells . Researchers who have used these approaches have demonstrated that Aβ deposits in AD mouse models were effectively cleared, and several of these approaches were subsequently tested in clinical settings [28, 59–61]. The aim of all of these approaches is to prevent the activation of CD4+ T-cell responses caused by the T-cell epitope located in the Aβ15-42 fragment. However, to date, no published clinical trial data or other evidence has shown that these approaches can be used to develop an effective vaccine against AD and prevent encephalitis or other adverse effects.
iTreg cells regulate T-cell-mediated immune reactions, thereby controlling autonomous immune responses. The use of Treg cells to treat inflammatory reactions has been considered a promising strategy, particularly against autoimmune diseases, allergies and asthma [62–65]. Although researchers have demonstrated powerful suppressive effects of iTreg against Teff cells in numerous studies, no strategy designed to develop an AD vaccine using iTregs to prevent T-cell-mediated brain inflammation has been tested. In our present study, we show for the first time that coimmunization of Aβ42 can indeed inhibit T cells by inducing iTreg cells in normal C57BL/6 mice (Additional file 1: Figure S1) and in APP695 mice (Figure 5).
To establish a link between iTreg cells and reduction of T-cell-mediated inflammation, we used an Aβ42-induced EAE model. The aim was to mimic the CD4+ T-cell infiltration into the brain that was observed with the use of AN-1792. We observed that this coimmunization significantly inhibited the formation of encephalitis by inducing a group of iTregs to inhibit the migration of CD4+ T cells into the brain. To conclusively demonstrate that the iTreg cells induced by coimmunization suppressed T-cell-mediated infiltration and inflammation in brain tissue, we adoptively transferred iTreg cells obtained from a donor mouse that had been coimmunized by the regimens into EAE-induced mice with inflammatory brain tissues. The results show that iTreg cells could indeed inhibit inflammatory CD4+ T-cell infiltration and thus reduce the number of T cells in brain tissue. Altogether, these results demonstrate that coimmunization inhibited the inflammatory response that was induced by the protein vaccine and that the inhibition was produced by induction of high levels of iTregs. The iTregs strongly suppressed CD4+ T-cell proliferation, inflammatory cytokine expression and migration into the inflammation site.
The data derived from our study of the APP695 mice described in this article demonstrate that the coimmunization regimens with Aβ42 protein and Aβ42-coding DNA induced both high titers of antibody against Aβ42, which effectively reduced plaque formation in this AD mouse model, and induced iTregs that strongly reduced brain inflammation and infiltration of T cells into the brain. AD development was ameliorated. Therefore, the results are a proof of concept and indicate that the coimmunization strategy reported herein should be further developed with the goal of testing it in human patients.
Cytometric bead array
Experimental autoimmune encephalomyelitis
Enhanced green fluorescent protein
Enzyme-linked immunosorbent assay
Induction of antigen-specific regulatory T cell
Naïve regulatory cell
We wish to thank Dr Jane QL Yu and Zhonghuai He for their assistance in this work. We are grateful to Mathias Jucker, Hertie Institute for Clinical Brain Research, Tübingen, Germany, for providing the APP/PS1 mice.
The present work was supported by the Chinese National Natural Science Foundation (30930068), Chinese High-Tech R&D Program (2012AA02A407) to BWa and by the Robert-Bosch-Stiftung, Wissenschaftsbrücke China to CK and BWa.
- Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS: Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005, 307: 1282-1288. 10.1126/science.1105681.View ArticlePubMedGoogle Scholar
- Golde TE, Schneider LS, Koo EH: Anti-Aβ therapeutics in Alzheimer’s disease: the need for a paradigm shift. Neuron. 2011, 69: 203-213. 10.1016/j.neuron.2011.01.002.PubMed CentralView ArticlePubMedGoogle Scholar
- Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297: 353-356. 10.1126/science.1072994. A published erratum appears in Science 2002, 297:2209View ArticlePubMedGoogle Scholar
- Klunk WE: Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011, 32: S20-S36.PubMed CentralView ArticlePubMedGoogle Scholar
- Bate C, Kempster S, Last V, Williams A: Interferon-γ increases neuronal death in response to amyloid-β1-42. J Neuroinflammation. 2006, 3: 7-10.1186/1742-2094-3-7.PubMed CentralView ArticlePubMedGoogle Scholar
- Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ, for the Alzheimer’s Disease Cooperative Study: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA. 2000, 283: 1007-1015. 10.1001/jama.283.8.1007. A published erratum appears in JAMA 2000, 283:2597View ArticlePubMedGoogle Scholar
- Nitsch R, Hock C: Targeting β-amyloid pathology in Alzheimer’s disease with Aβ immunotherapy. Neurotherapeutics. 2008, 5: 415-420. 10.1016/j.nurt.2008.05.013.View ArticlePubMedGoogle Scholar
- Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999, 400: 173-177. 10.1038/22124.View ArticlePubMedGoogle Scholar
- Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE: Evidence for impaired amyloid β clearance in Alzheimer’s disease. Alzheimers Res Ther. 2013, 5: 33-10.1186/alzrt187.PubMed CentralView ArticlePubMedGoogle Scholar
- Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, for the AN1792(QS-21)-201 Study Team: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005, 64: 1553-1562. 10.1212/01.WNL.0000159740.16984.3C.View ArticlePubMedGoogle Scholar
- Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S: Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology. 2005, 64: 94-101. 10.1212/01.WNL.0000148604.77591.67.View ArticlePubMedGoogle Scholar
- Moretto N, Bolchi A, Rivetti C, Imbimbo BP, Villetti G, Pietrini V, Polonelli L, Del Signore S, Smith KM, Ferrante RJ, Ottonello S: Conformation-sensitive antibodies against Alzheimer amyloid-β by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem. 2007, 282: 11436-11445. 10.1074/jbc.M609690200.View ArticlePubMedGoogle Scholar
- Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, Vasilevko V, Karapetyan A, Lees A, Agadjanyan MG, Cribbs DH: Mannan-Aβ28 conjugate prevents Aβ-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J Neuroinflammation. 2008, 5: 42-10.1186/1742-2094-5-42.PubMed CentralView ArticlePubMedGoogle Scholar
- Puras G, Salvador A, Igartua M, Hernández RM, Pedraz JL: Encapsulation of Aβ1–15 in PLGA microparticles enhances serum antibody response in mice immunized by subcutaneous and intranasal routes. Eur J Pharm Sci. 2011, 44: 200-206. 10.1016/j.ejps.2011.07.010.View ArticlePubMedGoogle Scholar
- Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, Fang XD, Hung CH, Hutter-Paier B, Windisch M: Site-specific UBITh amyloid-β vaccine for immunotherapy of Alzheimer’s disease. Vaccine. 2007, 25: 3041-3052. 10.1016/j.vaccine.2007.01.031.View ArticlePubMedGoogle Scholar
- Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, Jennings GT, Lüönd R, Ortmann R, Reichwald J, Zurini M, Mir A, Bachmann MF, Staufenbiel M: The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011, 31: 9323-9331. 10.1523/JNEUROSCI.0293-11.2011.View ArticlePubMedGoogle Scholar
- Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W: Development of AFFITOPE vaccines for Alzheimer’s disease (AD)–from concept to clinical testing. J Nutr Health Aging. 2009, 13: 264-267. 10.1007/s12603-009-0070-5.View ArticlePubMedGoogle Scholar
- Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A: Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. The Lancet Neurology. 2012, 11: 597-604. 10.1016/S1474-4422(12)70140-0.View ArticlePubMedGoogle Scholar
- Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T: Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000, 6: 916-919. 10.1038/78682.View ArticlePubMedGoogle Scholar
- Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T: Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc Natl Acad Sci U S A. 2003, 100: 2023-2028. 10.1073/pnas.0436286100. A published erratum appears in Proc Natl Acad Sci U S A 2004, 101:11526PubMed CentralView ArticlePubMedGoogle Scholar
- Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, Janus C, Lemere CA: Short amyloid-β (Aβ) immunogens reduce cerebral Aβ load and learning deficits in an Alzheimer’s disease mouse model in the absence of an Aβ-specific cellular immune response. J Neurosci. 2006, 26: 4717-4728. 10.1523/JNEUROSCI.0381-06.2006.View ArticlePubMedGoogle Scholar
- Wilcock DM, Colton CA: Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets. 2009, 8: 50-64. 10.2174/187152709787601858.PubMed CentralView ArticlePubMedGoogle Scholar
- Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D: Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003, 23: 3745-3751.PubMedGoogle Scholar
- Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN: Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 2007, 144: 950-960. 10.1016/j.neuroscience.2006.10.020.PubMed CentralView ArticlePubMedGoogle Scholar
- Wilcock DM, Morgan D, Gordon MN, Taylor TL, Ridnour LA, Wink DA, Colton CA: Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence. J Neuroinflammation. 2011, 8: 115-10.1186/1742-2094-8-115.PubMed CentralView ArticlePubMedGoogle Scholar
- Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer’s disease model. Nat Neurosci. 2002, 5: 452-457.PubMedGoogle Scholar
- DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2001, 98: 8850-8855. 10.1073/pnas.151261398.PubMed CentralView ArticlePubMedGoogle Scholar
- Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, Grundman M: A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010, 24: 198-203. 10.1097/WAD.0b013e3181c53b00.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, Lemere CA: MER5101, a novel Aβ1–15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PSΔ1E9 transgenic mice. J Neurosci. 2013, 33: 7027-7037. 10.1523/JNEUROSCI.5924-12.2013.PubMed CentralView ArticlePubMedGoogle Scholar
- Lambracht-Washington D, Qu B, Fu M, Anderson LD, Eagar TN, Stüve O, Rosenberg RN: A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. J Neuroimmunol. 2013, 254: 63-68. 10.1016/j.jneuroim.2012.09.008.PubMed CentralView ArticlePubMedGoogle Scholar
- Sakaguchi S, Setoguchi R, Yagi H, Nomura T: Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in self-tolerance and autoimmune disease. Curr Top Microbiol Immunol. 2006, 305: 51-66.PubMedGoogle Scholar
- Jin H, Kang Y, Zhao L, Xiao C, Hu Y, She R, Yu Y, Du X, Zhao G, Ng T, Chu HJ, Wang B: Induction of Adaptive T Regulatory Cells That Suppress the Allergic Response by Coimmunization of DNA and Protein Vaccines. J Immunol. 2008, 180: 5360-5372. 10.4049/jimmunol.180.8.5360.View ArticlePubMedGoogle Scholar
- Jin H, Kang Y, Zheng G, Xie Q, Xiao C, Zhang X, Yu Y, Zhu K, Zhao G, Zhang F, Chen A, Wang B: Induction of active immune suppression by co-immunization with DNA- and protein-based vaccines. Virology. 2005, 337: 183-191. 10.1016/j.virol.2005.03.029.View ArticlePubMedGoogle Scholar
- Li J, Geng S, Xie X, Liu H, Zheng G, Sun X, Zhao G, Wan Y, Wu Y, Chen X, Zhong Y, Wang B: Caveolin-1–Mediated Negative Signaling Plays a Critical Role in the Induction of Regulatory Dendritic Cells by DNA and Protein Coimmunization. J Immunol. 2012, 189: 2852-2859. 10.4049/jimmunol.1102828.View ArticlePubMedGoogle Scholar
- Chang Y, Zhu H, Cai YY: Construction and identification of eukaryotic expression vector of homo sapiens amyloid precursor protein (APP). Chin J Gerontol. 1999, 16: 42-44.Google Scholar
- Chang Y, Qin C, Yin H, Zhu H, Cai Y: Establishment of the transgenic model of Alzheimer’s disease. Acta Anat Sin. 2000, 31: 144-147.Google Scholar
- Feng Z, Chang Y, Cheng Y, Zhang B, Qu Z, Qin C, Zhang J: Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res. 2004, 37: 129-136. 10.1111/j.1600-079X.2004.00144.x.View ArticlePubMedGoogle Scholar
- Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jäggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Hölscher C, Mathews PM, Jucker M: Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7: 940-946. 10.1038/sj.embor.7400784.PubMed CentralView ArticlePubMedGoogle Scholar
- Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, Lee VMY, Kung HF: IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques. Brain Res. 2002, 956: 202-210. 10.1016/S0006-8993(02)03436-4.View ArticlePubMedGoogle Scholar
- Bussière T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, Schenk D, Games D, Seubert P, Buttini M: Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance. Am J Pathol. 2004, 165: 987-995. 10.1016/S0002-9440(10)63360-3.PubMed CentralView ArticlePubMedGoogle Scholar
- Meerlo P, Overkamp GJ, Benning MA, Koolhaas JM, Van den Hoofdakker RH: Long-term changes in open field behaviour following a single social defeat in rats can be reversed by sleep deprivation. Physiol Behav. 1996, 60: 115-119. 10.1016/0031-9384(95)02271-6.View ArticlePubMedGoogle Scholar
- Liang KC, Hon W, Tyan YM, Liao WL: Involvement of hippocampal NMDA and AMPA receptors in acquisition, formation and retrieval of spatial memory in the Morris water maze. Chin J Physiol. 1994, 37: 201-212.PubMedGoogle Scholar
- Wang D, Gao K, Li X, Shen X, Zhang X, Ma C, Qin C, Zhang L: Long-term naringin consumption reverses a glucose uptake defect and improves cognitive deficits in a mouse model of Alzheimer's disease. Pharmacol Biochem Behav. 2012, 102: 13-20. 10.1016/j.pbb.2012.03.013.View ArticlePubMedGoogle Scholar
- Kang Y, Sun Y, Zhang J, Gao W, Kang J, Wang Y, Wang B, Xia G: Treg Cell Resistance to Apoptosis in DNA Vaccination for Experimental Autoimmune Encephalomyelitis Treatment. PLoS One. 2012, 7: e49994-10.1371/journal.pone.0049994.PubMed CentralView ArticlePubMedGoogle Scholar
- Cissé M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L: Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci. 2011, 31: 10427-10431. 10.1523/JNEUROSCI.1459-11.2011. A published erratum appears in J Neurosci 2011, 31:14046PubMed CentralView ArticlePubMedGoogle Scholar
- Kobayashi DT, Chen KS: Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav. 2005, 4: 173-196. 10.1111/j.1601-183X.2005.00124.x.View ArticlePubMedGoogle Scholar
- Meilandt WJ, Cissé M, Ho K, Wu T, Esposito LA, Scearce-Levie K, Cheng IH, Yu GQ, Mucke L: Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Aβ oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci. 2009, 29: 1977-1986. 10.1523/JNEUROSCI.2984-08.2009.PubMed CentralView ArticlePubMedGoogle Scholar
- Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G: Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain. 2003, 126: 285-291. 10.1093/brain/awg031.View ArticlePubMedGoogle Scholar
- Li J, Geng S, Liu X, Liu H, Jin H, Liu CG, Wang B: DNA and protein co-administration induces tolerogenic dendritic cells through DC-SIGN mediated negative signals. Hum Vaccin Immunother. 2013, 9: 2237-2245.PubMed CentralView ArticlePubMedGoogle Scholar
- Zheng L, Wang F, Yang Z, Chen J, Chang H, Chen Z: A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect Dis. 2009, 9: 17-10.1186/1471-2334-9-17.PubMed CentralView ArticlePubMedGoogle Scholar
- Griffin WS, Liu L, Li Y, Mrak RE, Barger SW: Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation. 2006, 3: 5-10.1186/1742-2094-3-5.PubMed CentralView ArticlePubMedGoogle Scholar
- Veerhuis R, Janssen I, De Groot CJ, Van Muiswinkel FL, Hack CE, Eikelenboom P: Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp Neurol. 1999, 160: 289-299. 10.1006/exnr.1999.7199.View ArticlePubMedGoogle Scholar
- Kensil CR, Kammer R: QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs. 1998, 7: 1475-1482. 10.1517/135437184.108.40.2065.View ArticlePubMedGoogle Scholar
- Ragupathi G, Gardner JR, Livingston PO, Gin DY: Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines. 2011, 10: 463-470. 10.1586/erv.11.18.PubMed CentralView ArticlePubMedGoogle Scholar
- Tovey MG, Lallemand C: Adjuvant activity of cytokines. Methods Mol Biol. 2010, 626: 287-309. 10.1007/978-1-60761-585-9_19.View ArticlePubMedGoogle Scholar
- Libbey JE, Fujinami RS: Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines. Vaccine. 2011, 29: 3356-3362. 10.1016/j.vaccine.2010.08.103.PubMed CentralView ArticlePubMedGoogle Scholar
- Mills KH: TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol. 2011, 11: 807-822.PubMedGoogle Scholar
- Batista-Duharte A, Lindblad EB, Oviedo-Orta E: Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol Lett. 2011, 203: 97-105. 10.1016/j.toxlet.2011.03.001.View ArticlePubMedGoogle Scholar
- Eisai Co Ltd: [News Release, Vol. 9]. Eisai Announces The Start of the First Clinical Study of BAN2401, a Novel Monoclonal Anti-body Targeting the Neurotoxic Protofibrils Believed to Cause Alzheimer’s Disease. 2010, Tokyo: Eisai Co, Ltd, 11-40.Google Scholar
- Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WM, McCush F, Alvey C, Kupiec JT, Bednar MM: Safety and pharmacokinetics following a single 10-minute intravenous infusion of the anti-amyloid mAb ponezumab (PF-04360365) in patients with mild to moderate Alzheimer’s disease [Abstract]. Alzheimers Dement. 2010, 6: S585-View ArticleGoogle Scholar
- Goto T, Fujikoshi S, Uenaka K, Nishiuma S, Siemers ER, Dean RA, Takahashi M: Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer’s disease in a multicenter, randomized, open-label, multi-dose study [Abstract]. Alzheimers Dement. 2010, 6: S308-View ArticleGoogle Scholar
- Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA: Antigen-specific TGF-β1 secretion with bovine myelin oral tolerization in multiple sclerosis. Ann N Y Acad Sci. 1996, 778: 251-257. 10.1111/j.1749-6632.1996.tb21133.x.View ArticlePubMedGoogle Scholar
- Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997, 389: 737-742. 10.1038/39614.View ArticlePubMedGoogle Scholar
- Roncarolo MG, Battaglia M: Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol. 2007, 7: 585-598. 10.1038/nri2138.View ArticlePubMedGoogle Scholar
- Buckner JH: Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010, 10: 849-859. 10.1038/nri2889.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.